Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease

Journal of Neuroscience

Volumn 16, Issue 22, 1996, Pages 7206-7215

  Winkler, Christian ^a,b   Sauer, Hansjörg ^a,c   Lee, Chong S ^a,d   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

^b NORDSTADT HOSPITAL   (Germany)

^c GENENTECH INC   (United States)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

behavior; GDNF; neurodegeneration; Parkinson's disease; striatum; substantia nigra

Indexed keywords

NEURITE PROMOTING FACTOR;

ANIMAL MODEL; ARTICLE; BRAIN PROTECTION; DOPAMINERGIC NERVE CELL; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 0029803454     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.16-22-07206.1996     Document Type: Article

References (27)

1. Beck KD, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen RA, Rosenthal A, Hefti F (1995) Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373:339-341.
2. Bowenkamp KE, Hoffman AF, Gerhardt GA, Henry MA, Biddle PT, Hoffer BJ, Granholm AE (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 355:479-489.
3. Cheramy A, Leviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289:537-542.
4. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD (1983) Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol Scand 522:29-37.
5. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional specificity. Brain 114:2283-2301.
6. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255.
7. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111.
8. Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, Mackerlova L, Lile JD, Collins F, Hoffer BJ (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432.
9. Jenkins R, O'Shea R, Thomas KL, Hunt SP (1993) C-jun expression in substantia nigra neurons following striatal 6-hydroxydopamine neurons in the rat. Neuroscience 53:447-455.
10. Kearns CM, Gash DM (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111.
11. Lee CS, Sauer H, Björklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72:641-653.
12. Lin LF, Doherty D, Lile J, Bektesh S, Collins F (1993) A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
13. Mandel RJ, Brundin P, Björklund A (1990) The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur J Neurosci 2:888-894.
14. McGeer PL, Itagaki S, Akiyama H, Mc Geer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24:574-576.
15. Nikkhah G, Bentlage C, Cunningham MG, Björklund A (1994) Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J Neurosci 14:3449-3461.
16. Olsson M, Nikkhah G, Bentlage C, Björklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863-3875.
17. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd Ed. San Diego: Academic.
18. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647.
19. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm Park Dis Dement Sect 38:277-301.
20. Robertson HA (1992) Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 15:201-206.
21. Sagot Y, Tan SA, Hammang JP, Aebischer P, Kato AC (1996) GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice. J Neurosci 16:2335-2341.
22. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal neurons following intrastriatal terminal lesions with 6-OHDA: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415.
23. Sauer H, Rosenblad C, Björklund A (1995) GDNF but not TGF-β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine-lesion. Proc Natl Acad Sci USA 92:8935-8939.
24. Sawle GV, Myers R (1993) The role of positron emission tomography in the assessment of human neurotransplantation. Trends Neurosci 16:172-176.
25. Schallert T, Hall S (1988) Disengage sensorimotor deficit following apparent recovery from unilateral dopamine depletion. Behav Brain Res 30:15-24.
26. Tomac A, Lindquist E, Lin LF, Ögren SO, Young D, Hoffer BJ, Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339.
27. Ungerstedt U, Arbuthnott G (1970) Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493.